Evidence-guided tumor profiling to individualize therapy decisions.

Slides:



Advertisements
Similar presentations
1Kitasato-Harvard Symposium 10/03/2002 New Monoclonal Antibody Approved for Advanced Breast Cancer Shin-ichi Nihira, Ph.D. Dept. Clinical Research 3 Chugai.
Advertisements

Triple negative breast cancer
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in HER2- Positive, First-Line Metastatic Breast Cancer (MBC) Baselga.
Metastatic HER2-Positive Breast Cancer: Treatment Selection and Sequencing in the First Line and Beyond Moderator: Joseph Gligorov, MD, PhD Head, Cancer.
Comparison of Mutations and Protein Expression in Potentially Actionable Targets in 5500 Triple Negative vs. non-Triple Negative Breast Cancers Joyce A.
William J. Gradishar MD, FACP Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center For Women's Cancer Care Robert H. Lurie Comprehensive.
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Molecular Testing of lung cancer in routine practice
KRAS testing in colorectal cancer: an overview. 2 What is KRAS? KRAS is a gene that encodes one of the proteins in the epidermal growth factor receptor.
Northern England Strategic Clinical Network Conference Thyroid Sub-group Update Dr Sath Nag Consultant Endocrinologist Vice Chair, Thyroid NSSG South Tees.
HIGHLIGHTS IN THE MANAGEMENT OF BREAST CANCER
Targeted Therapy: A Giant Step Forward
KRAS testing in colorectal cancer
KRAS is mutated in about 40% of colorectal cancers; it is the only validated predictive marker used in patients with metastatic CRC 1. It is also a negative.
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Monoclonal antibodies in solid tumors.
Understanding and Treating Triple-Negative Breast Cancer Elshami M. Elamin, MD Medical Oncologist Central Care Cancer Center Wichita,
Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.
Assistant Professor of Medicine Dana-Farber Cancer Institute
Drug Treatment of Metastatic Breast Cancer
First-Line TKI Use in EGFR Mutation-Positive NSCLC
EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.
Margaret Tempero, M.D. Professor of Medicine University of California, San Francisco Debate: This house believes that FOLFIRINOX is the best treatment.
New Developments in Cancer Treatment Dulcinea Quintana, MD.
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Challenges in Incorporating Integral NGS into Early Clinical Trials
Van Cutsem E et al. ASCO 2009; Abstract LBA4509. (Oral Presentation)
GI-NEUROENDOCRINE TUMORS THERAPEUTIC APROACHES Chemotherapy: older and recent schemes Ilias Athanasiadis, MD Medical Oncologist Director of the Oncology.
Use of Chemotherapeutic and Biologic Agents in Metastatic Breast Cancer Breast Cancer Update Medical Oncology Educational Forum May 21, 2005 Kathy D Miller.
Eric Van Cutsem Head, Digestive Oncology, University Hospital Gasthuisberg and Professor of Internal Medicine, University of Leuven, Belgium Published.
Trials of Adjuvant Trastuzumab in HER2+ Early-Stage Breast Cancer Trial Study Regimen No. of Patients Disease-Free Survival (%) Hazard Ratio P-Value Overall.
Herceptin ® : leading the way in metastatic breast cancer care Steffen Kahlert.
Treatment for metastatic bladdercancer (chemotherapy&radiotherapy) Dr.Mina Tajvidi oncologist.
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
Fernando Cotait Maluf Diretor do Departamento de Oncologia Clínica Centro de Oncologia-Hospital São José Fernando Cotait Maluf Diretor.
Mace L. Rothenberg, M.D. Professor of Medicine Ingram Professor of Cancer Research Biomarkers in Colorectal Cancer Management: KRAS Mutations and EGFR.
KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
Cortés J et al. ASCO 2009; Abstract (Poster Discussion)
Overall survival in NSCLC
High Response Rates to Crizotinib in Advanced, Chemoresistant ALK+ Lymphoma Patients 1 Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive.
Taxanes — Taxanes are among the most active agents for metastatic breast cancer – Docetaxel, Paclitaxel, NabPaclitaxel. Anthracyclines – Doxorubicin, Epirubicin,
Challenges for the treatment of pancreatic and renal cell cancer Nick Thatcher Christie Hospital NHS Trust Manchester, UK.
CD-1 Second-line Chemotherapy for Hormone Refractory Prostate Cancer Disease Background Nicholas J. Vogelzang, MD Director Nevada Cancer Institute CD-1.
Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.
A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.
Responses to Subsequent Anti-HER2 Therapy After Treatment with Trastuzumab-DM1 in Women with HER2- Positive Metastatic Breast Cancer 1 A Phase Ib/II Trial.
A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.
Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.
TARGETED CANCER THERAPY IN 2016: WHAT THE PRACTICING PATHOLOGIST OR ONCOLOGIST NEEDS TO KNOW (SUPPLEMENTARY SLIDES) Steven J. Kussick, MD, PhD Associate.
Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.
The Center for Personalized Diagnostics: Past, Present, and FUTURE
Challenges for the treatment of breast cancer
Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)
A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer.
Value of Sequencing-Guided Treatment for Patients with
Potential actionable targets in appendiceal cancer detected by immunohistochemistry (IHC), fluorescent in situ hybridization (FISH) and mutational analysis.
MCW Regional Cancer Therapy Program
What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard
Caris Molecular Intelligence®
Unità Clinica di Diagnostica Istopatologica e Molecolare
The New Taxonomy of Metastatic NSCLC and Physician Treatment Based on Pathologic and Molecular Characteristics The New Taxonomy of Metastatic Non-Small.
Krop I et al. SABCS 2009;Abstract 5090.
Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011
Adam L. Cohen, MD, MS Assistant Professor Division of Oncology
Chapter 3 Treatment guidelines for NSCLC that does not have targetable driver mutations.
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.
Esteller, New England Journal of Medicine, 2008
Presentation transcript:

Evidence-guided tumor profiling to individualize therapy decisions

How Genomics Accelerates Personalized Medicine EGFR mutants ALK ROS1 HER2 B-raf K-ras PERSONALIZED MEDICINE

Caris Life Sciences American bioscience company focused on developing and delivering innovative molecular diagnostic, prognostic and theranostic services to the treatment of cancer Leading company with with over tumors profiled since 2008 Partner in Romania: Farmaceutica Remedia Distribution & Logistics SRL

Caris Molecular Intelligence (CMI) Molecular profiling service Uses a multitechnology approach to investigate patient’s tumor: IHC, FISH/CISH, NGS, PCR, Sanger sequencing, Pyrosequencing, Fragment analysis Correlates biomarker targets to therapeutic agents, based on an extensive clinical literature assessment Reports agents associated with potential benefit and lack of benefit in an actionable report Identifies relevant clinical trials based on the biomarker unique profile

CMI helps in patients with therapeutic ambiguities Patients with uncommon or aggressive tumours, for whom there is no standard of care Patients in whom standard of care options have failed Patients who are fit, willing and needing further therapy 5 Patient with basal cell carcinoma Profiling found Hedgehog mutation Treatment with Hedgehog inhibitor led to CR Courtesy: Daniel Von Hoff, NEJM, 2009

Key Challenge 6 Typical Case 18 IHCs 3-6 CISH/FIS H 46+ gene NGS Need to optimize/prioritize tissue availability to most informative testing and maximize DNA yield

What Are My Options?? 7 How do I treat a patient with breast cancer where standard treatment options have failed? In fact, the treatment decision will already be individualised and based on local practice guidelines, physician experience, clinical judgement, patient physical condition and medical history Try A Different Cytotoxic Agent Rechallenge with a Prior Treatment Consider a Clinical Trial ?? Anthracyclines or Antimetabolites Hormone Therapy Off-label treatment ?? Taxanes or Abraxane Trastuzumab ?? Which One? cMET inhibitors, BRAF or MEK inhibitors PIK3Ca, mTOR, MEK, angiogenesis or IGF pathway inhibitors ??

Many Biomarkers are Linked with Therapeutic Options 8 How do I treat a patient with breast cancer where standard treatment options have failed? TOPO1 (IHC) TS (IHC) RRM1 (IHC) BRAF (NGS) MGMT (IHC) ER (IHC), HER2 (IHC), HER2 (CISH), PIK3CA (NGS) SPARC (IHC), TLE3 (IHC), Pgp (IHC) ER (IHC) or PR (IHC) HER2 (IHC), HER2 (CISH), PTEN (IHC), PIK3CA (NGS) cKIT (NGS), PDGFRa (NGS) TOPO2A (FISH) and HER2 (CISH) HER2 (IHC) or HER2 (CISH) RET (NGS) irinotecan fluorouracil, capecitabine, pemetrexed gemcitabine vemurafenib temozolomide, dacarbazine everolimus, temsirolimus paclitaxel, docetaxel, nab-paclitaxel hormone therapy trastuzumab imatinib doxorubicin, liposomal-doxorubicin, epirubicin lapatinib, pertuzumab, TDM-1 vandetanib

Each Biomarker Result May Help You Select Therapies How do I treat a patient with breast cancer where standard treatment options have failed? TOPO1 (IHC) TS (IHC) RRM1 (IHC) BRAF (NGS) MGMT (IHC) ER (IHC), HER2 (IHC), HER2 (CISH), PIK3CA (NGS) SPARC (IHC), TLE3 (IHC), Pgp (IHC) ER (IHC) or PR (IHC) HER2 (IHC), HER2 (CISH), PTEN (IHC), PIK3CA (NGS) cKIT (NGS), PDGFRa (NGS) TOPO2A (FISH) and HER2 (CISH) HER2 (IHC) or HER2 (CISH) RET (NGS) CONSIDER irinotecan AVOID fluorouracil, capecitabine, pemetrexed CONSIDER gemcitabine AVOID vemurafenib CONSIDER temozolomide, dacarbazine AVOID everolimus, temsirolimus AVOID paclitaxel, docetaxel, nab-paclitaxel AVOID hormone therapy CONSIDER trastuzumab CONSIDER imatinib CONSIDER doxorubicin, liposomal-doxorubicin, epirubicin CONSIDER lapatinib, pertuzumab, TDM-1 AVOID vandetanib Biomarker associated with potential benefit Biomarker associated with potential lack of benefit

Biomarker Results Are Actionable 10 How do I treat a patient with breast cancer where standard treatment options have failed? irinotecan fluorouracil, capecitabine, pemetrexed gemcitabine vemurafenib temozolomide, dacarbazine everolimus, temsirolimus paclitaxel, docetaxel, nab-paclitaxel hormone therapy trastuzumab imatinib doxorubicin, liposomal-doxorubicin, epirubicin lapatinib, pertuzumab, TDM-1 vandetanib SELECT AGENTS FROM AVOID AGENTS FROM Based on Biomarker Results Associated with Potential BENEFIT Based on Biomarker Results Associated with Potential BENEFIT Based on Biomarker Results Associated with Potential LACK OF BENEFIT Based on Biomarker Results Associated with Potential LACK OF BENEFIT In fact, the treatment decision will still be individualised and based on local practice guidelines, physician experience, clinical judgement, patient physical condition and medical history BUT PUT INTO THE CONTEXT AND UNDERSTANDING OF COMPREHENSIVE & PREDICTIVE BIOMARKER TESTING

Evidence Can Support Off-Label Treatment Options 11 How do I treat a patient with breast cancer where standard treatment options have failed? irinotecan fluorouracil, capecitabine, pemetrexed gemcitabine vemurafenib temozolomide, dacarbazine everolimus, temsirolimus paclitaxel, docetaxel, nab-paclitaxel hormone therapy trastuzumab imatinib doxorubicin, liposomal-doxorubicin, epirubicin lapatinib, pertuzumab, TDM-1 vandetanib SELECT AGENTS FROM AVOID AGENTS FROM Based on Biomarker Results Associated with Potential BENEFIT Based on Biomarker Results Associated with Potential BENEFIT Based on Biomarker Results Associated with Potential LACK OF BENEFIT Based on Biomarker Results Associated with Potential LACK OF BENEFIT 13 of 25 patients experienced clinical benefit A Pilot Study Utilizing Molecular Profiling to find Potential Targets and Select Individualized Treatments for Patients with Metastatic Breast Cancer Jameson et al., ASCO 2013 A Pilot Study Utilizing Molecular Profiling to find Potential Targets and Select Individualized Treatments for Patients with Metastatic Breast Cancer Jameson et al., ASCO patients with heavily pretreated (4-12 prior lines) metastatic breast cancer received MP-guided treatments 9 of those 13 patients received an irinotecan-containing regimen (PFS 86 – 892+ days) 9 of those 13 patients received an irinotecan-containing regimen (PFS 86 – 892+ days)

Report available on paper and online 12 Provide a rationale for your next treatment To Determine What Not to Use Identify therapies which may not have been considered

Overall clinical benefit in 27% - 60% of patients 13 v v v v v

Independent & Supportive Clinical Evidence for Caris Molecular Intelligence Is Accumulating Globally 14 Von Hoff DD et al. [2010] J Clin Oncol Nov 20; 28(33): Popovtzer A. et al. [2012] Presented at 8 th AHNS International Conference on Head and Neck Cancer (Abstract Number S172) Epelbaum R. et al. [2013] J Clin Oncol; 30 suppl 34; abstr 195 Jameson G. et al. [2013] J Clin Oncol (suppl; abstr TPS11123) Dean A. et al. [2013] Abstract presented at 2013 ECCO meeting

Clinical Experience with CMI Dan von Hoff, 2010: Pilot study on refractory cancers Gayle Jameson, 2014: Breast Cancer Study Ramesh Ramanathan, 2012: Pancreatic Cancer Study Andrew Dean, 2013: Rare and refractory solid tumors Aaron Popovtzer, 2012: Head &Neck Cancer Ron Epelbaum, 2013: Pancreatic Cancer Kate Oliver, 2013:Ovarian Cancer Registry In 134 patients the treatment decision prior to CMI, actual treatments, and outcomes were registered

16 G. Jameson et al.: CMI for metastatic breast cancer Gayle Jameson et al., ASCO 2013

Breast cancer study details patients with prior regimens 5 patients changed receptor status Treatment decision revised in all patients 13/25 (52%) had clinical benefit 9/13 had an Irinotecan containing regimen Molecular Profiling guided treatments: 19 chemotherapy 6 hormone 6 TKI 3 monoclonal antibody Gayle Jameson et al., Breast Cancer Res Treat 2014

18 ©2013 Caris Life Sciences and affiliates. Andrew Dean et al.; ECCO patients with rare cancer, 28 heavily pretreated patients 60% clinical benefit in patients with rare cancer 54% clinical benefit in heavily pretreated patients Overall: 26/29 chemotherapy 3/29 TKI

Adenoid cystic carcinoma of the salivary gland: Uncommon tumor with no established standard of care 11 patients diagnosed in 2011/12, 6 received CMI guided therapy Hormone therapy 2 Monochemotherapy2 Combination chemotherapy2 Very encouraging clinical results: 4/6 at least partial remission of >6 months one complete remission >15 months Source: Bio-marker driven tailored treatment for metastatic adenoid cystic carcinoma; Popovtzer A; 8 th international conference on head and neck cancer, Toronto July 2012, S172. Aaron Popovtzer et al., 2012

CMI guided therapy for advanced pancreatic cancer 20 Ron Epelbaum et al., ASCO GI 2013: 29 Molecular Profiling guided treatments: 13 combination chemotherapy 8 chemotherapy alone 6 chemotherapy with TKI 2 TKI alone Clinical benefit rate: 37.5%

CMI guided therapy for advanced pancreatic cancer 21 Ramesh Ramanathan et al., AACR 2012: 36 Molecular Profiling guided treatments: 22 combination chemotherapy 12 monochemotherapy 2 chemotherapy with TKI Median survival: 5 months

Drug selection for CMI-guided therapies 134 patients evaluated – Conventional chemotherapy11284% – Tyrosine kinase inhibitors 2116% – Hormone therapy 8 6% – Monoclonal antibodies 3 2% Treatment decision was revised in almost all patients Actionable biomarker results in over 95% of patients 22

Caris Molecular Intelligence can help to 23 Evidence-based rationale for your next treatment decision SELECT Determine what not to use AVOID Identify therapies which may not have been considered EXPAND

Personalized Medicine at your fingertips Comprehensive & Predictive Biomarker Testing Key Supportive Literature An Actionable Report for Your Patient